-+ 0.00%
-+ 0.00%
-+ 0.00%

NeOnc reports Phase 2a NEO100 trial hits six-month PFS endpoint in recurrent IDH1-mutant high-grade glioma

PUBT·08/12/2026 12:08:28
Listen to the news
NeOnc reports Phase 2a NEO100 trial hits six-month PFS endpoint in recurrent IDH1-mutant high-grade glioma
  • NeOnc reported positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma.
  • Results were announced now; the full Phase 2a dataset is expected to be presented at a future medical meeting.
  • Study met its primary endpoint, supporting a meaningful delay in disease worsening versus standard expectations in this setting.
  • Survival outcomes were described as encouraging, with several patients remaining on treatment and signs of durable disease control.
  • Safety profile appeared favorable, with no major toxicities reported; NeOnc plans an FDA Type B meeting to discuss a registrational path.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120800PRIMZONEFULLFEED9808297) on August 12, 2026, and is solely responsible for the information contained therein.